Search

Displaying results 371 - 380 of 4539 in total
  1. Drug

    Etonogestrel

    go.drugbank.com/drugs/DB00294
    ApprovedInvestigational

    [A37184] The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001.[L5692]

  2. Drug

    Trofinetide

    go.drugbank.com/drugs/DB06045
    Approved

    [A258438] Trofinetide was approved by the FDA on March 10, 2023, for the treatment of Rett syndrome,[L45718,L45748] which is an X-linked neurodevelopmental disorder characterized by a range of cognitive … [A258438] Trofinetide is believed to work by reducing inflammation and apoptosis of neurons.

  3. Drug

    Roflumilast

    go.drugbank.com/drugs/DB01656
    ApprovedInvestigational

    The cream formulation was first approved by the FDA in July 2022 [L42580] and by Health Canada in April 2023. … [L46541] On December 15, 2023, the FDA approved a new topical foam formulation of roflumilast for the treatment of seborrheic dermatitis in patients aged 9 years and older.[L49281]

  4. Drug

    Pegzilarginase

    go.drugbank.com/drugs/DB14780
    Approved

    FDA in February 2026 for the treatment of hyperargininemia in adult and pediatric patients aged 2 years and older with ARG1-D, to be used in conjunction with dietary protein restriction. … [L56053] By substituting the native manganese cofactor with cobalt to enhance catalytic activity, this agent effectively degrades elevated plasma arginine into ornithine and urea, thereby mitigating the

  5. Drug

    Peanut oil

    go.drugbank.com/drugs/DB13964
    ApprovedWithdrawn

    The kernels are consumed roasted but a large percentage is used for the production of vegetable oil.

  6. Drug

    Brensocatib

    go.drugbank.com/drugs/DB15638
    Approved

    [A274348] Brensocatib was approved by the US FDA on August 12, 2025, for use in adults and pediatric patients with NCFB.[L53808,L53813] … Non-cystic fibrosis bronchiectasis (NCFB) is a chronic lung disease characterized by airway widening, mucus accumulation, and neutrophilic inflammation.

  7. Drug

    Secukinumab

    go.drugbank.com/drugs/DB09029
    ApprovedInvestigational

    [A249840] Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). … [L39600] By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders.

  8. Drug

    Dextrose, unspecified form

    go.drugbank.com/drugs/DB09341
    ApprovedInvestigationalVet approved

    Glucose is a simple sugar (monosaccharide) generated during phosynthesis involving water, carbon and sunlight in plants. It is produced in humans via hepatic gluconeogenesis and breakdown of polymeric glucose forms (glycogenolysis). It c...

    Mixtures: HIDROLITE MK POLVO PARA REHIDRATACIONORAL, INFUSOL K+0.15 D5 (Potassium Chloride 0.15% w/v and Dextrose 5% w/v Intravenous Infusion BP)
  9. Drug

    Azelastine

    go.drugbank.com/drugs/DB00972
    ApprovedInvestigational

    combination with fluticasone propionate as a nasal spray marketed under the trade name Dymista™, which is indicated for the symptomatic treatment of seasonal allergic rhinitis in patients 6 years of age and older

  10. Drug

    AstraZeneca COVID-19 Vaccine

    go.drugbank.com/drugs/DB15656
    ApprovedInvestigational

    [L12669] The trial is taking place in the UK, where the vaccine will be administered intramuscularly to healthy adult volunteers between the ages of 18 and 55.[L12669] … development and distribution deal with AstraZeneca in May 2020[L32659] which paved the way for the vaccine's subsequent approval and usage in dozens of regions across the globe, including Canada, Mexico, the UK